medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2010, Number 4

<< Back Next >>

Rev Esp Med Quir 2010; 15 (4)

DNA repair ways: new targets in the therapy against cancer

Díaz CJ, Domínguez GG

Language: Spanish
References: 38
Page: 221-227
PDF size: 74.60 Kb.


ABSTRACT

Increased chemo-resistance and radio-resistance of cancer cells is a major obstacle in the treatment and management of cancer. An important mechanism that underlies the development of such therapeutic resistance is that cancer cells recognize DNA lesions induced by DNA-damaging agents and by ionizing radiation, and repair these lesions by activating various DNA repair pathways. Therefore, inhibitors of specific DNA repair pathways might prove efficacious when used in combination with DNA-damaging chemotherapeutic drugs and reversing the associated therapeutic resistance associated with DNA repair. This paper reviews the major DNA repair pathways and discusses recent advances in the development of novel inhibitors of DNA repair pathways; many of these agents are under preclinical/clinical investigation.


REFERENCES

  1. Wade Harper J, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007;28:739-45.

  2. O’Connor MJ, Martin NMB, Smith GCM. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007;26:7816-7824.

  3. Zhu Y, Hu J, Hu Y, Liu W. Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. Cancer Treat Rev 2009;35:590-596.

  4. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-254.

  5. Yu TW, Anderson D. Reactive oxygen species-induced DNA damage and its modification: a chemical investigation. Mutat Res 1997;379:201-210.

  6. Kuzminov A. Single-strand interruptions in replicating chromosomes cause double-strand breaks. Proc Natl Acad Sci USA 2001;98:8241-8246.

  7. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, et al. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005;25:7158-7169.

  8. Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008;18:99-113.

  9. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002;2:188-200.

  10. Lawley PD, Phillips DH. DNA adducts from chemotherapeutic agents. Mutat Res 1996;355:13-40.

  11. Bouziane M, Miao F, Ye N, Holmquist G, et al. Repair of DNA alkylation damage. Acta Biochim Pol 1998;45:191-202.

  12. Kinsella AR, Smith D. Tumor resistance to antimetabolites. Gen Pharmacol 1998;30:623-626.

  13. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.

  14. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003;193:3-34.

  15. Stupp, R, Mason WP, van den Bent MJ, Weller M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.

  16. Gerson SL, Berger NA, Arce C, Petzold SJ, Willson JK. Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine. Biochem Pharmacol 1992; 43:1101-1107.

  17. Middleton MR, Margison GP. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 2003;4:37-44.

  18. Quinn JA, Desjardins A, Weingart J, Brem H, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005;23:7178-7187.

  19. Khan O, Middleton MR. The therapeutic potential of O6- alkylguanine DNA alkyltransferase inhibitors. Expert Opin Investig Drugs 2007;16:1573-1584.

  20. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly (ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-382.

  21. Donawho CK, Luo Y, Luo Y, Pennig TD, et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-2737.

  22. Zhao Y, Thomas HD, Batey MA, Cowell IG, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66:5354-5362.

  23. Bryant HE, Schultz N, Thomas HD, Parker KM, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434;913-917.

  24. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511-518.

  25. Helleday T, Bryant HE, Schultz N. Poly (ADPribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005; 4:1176-1178.

  26. McCabe N, Turner NC, Lord CJ, Kluzek K, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-8115.

  27. Bryant HE, Helleday T. Inhibition of poly (ADPribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006;34:1685-1691.

  28. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, et al. Inhibition of ATM and ATR kinase activities by the radiosensitising agent, caffeine. Cancer Res 1999;59:4375-4382.

  29. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Gene Dev 1999;13:152-157.

  30. Ribeiro JC, Barnetson AR, Jackson P, Ow K, et al. Caffeineincreased radiosensitivity is not dependent on a loss of G2/M arrest or apoptosis in bladder cancer cell lines. Int J Radiat Biol 1999;75:481-492.

  31. Graves PR, Yu L, Schwarz JK, Gales J, et al. The CHK1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5605.

  32. Hotte SJ, Oza A, Winquist EW, Moore M, et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret hospital phase II consortium study. Ann Oncol 2006;17:334-340.

  33. Hickson I, Zhao Y, Richardson CJ, Green SJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9159.

  34. Stewart GS, Maser RS, Stankovic T, Bressan DA, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999; 99:577-587.

  35. Girard PM, Foray N, Stumm M, Waugh A, et al. Radiosensitivity in Nijmegen Breakage Syndrome cells is attributable to a repair defect and not cell cycle checkpoint defects. Cancer Res 2000; 60:4881-4888.

  36. Cariveau MJ, Tang X, Cui XL, Xu B. Characterization of an NBS1 C-terminal peptide that can inhibit ataxia telangiectasia mutated (ATM)-mediated DNA damage responses and enhance radiosensitivity. Mol Pharmacol 2007;72:320-326.

  37. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyperreplication. Nature 2006;444:638-642.

  38. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-913.




2020     |     www.medigraphic.com